While current treatments for autism focus on surface-level behaviors, we are designing therapies that reflect the diverse biology behind symptom presentation. Our goal is to replace one-size-fits-all suppressive drugs with more targeted, better tolerated, and functionally meaningful solutions.
Current paradigm utilize anti-psychotics which suppress the whole child—dampening behavior, mood, and personality—without improving cognition or daily function.
Side effects, complex dosing, or inefficacy often result in poor long-term adherence.
Generic models overlook the diversity of ASD presentations and individual needs.
Our therapies target the precise biological pathways that drive core symptoms, helping children think more clearly, engage more fully, and be more themselves.
We design with tolerability in mind—avoiding sedation, metabolic disruption, and overmedication
Our pipeline is modular by design, with each program built for a specific biologic & symptomatic domain such as cognition, emotion, or motor coordination.
At Remi Therapeutics, we believe that better outcomes start with a better understanding of biology. Our therapies are built to address the specific biological disruptions behind core autism symptoms—from inflammation and oxidative stress to neurotransmitter imbalance and mitochondrial dysfunction.
Each compound in our pipeline is matched to a distinct functional challenge: cognition, emotional regulation, or motor coordination. By designing for these domains, we aim to improve not just behaviors, but how individuals with autism engage with the world around them.
Autism is one of the fastest growing therapeutic areas in the world, yet families still face a system built around outdated treatments. Most available therapies were not designed to treat the biology of autism, leading to limited outcomes and difficult tradeoffs.
We see a new path forward—one that reflects the biology behind core symptoms and the urgency families feel every day.
The Global Autism market size was valued at $4.5 Billion in 2024
Projected market by 2030, growing at over 6 percent CAGR
The majority of people with autism experience co-occurring conditions like ADHD, anxiety, or motor dysfunction—highlighting the need for therapies tailored to diverse symptom biology.
We are scientists, clinicians, and biotech veterans united by one mission—to develop smarter therapies for autism that reflect the complexity of the biology and the daily realities of families.
Our team has launched over 30 products, raised millions of dollars in prior ventures, and led programs from discovery through approval. Together, we are building a new model for how neurodevelopmental and neuroimmune disorders are treated.
